医学
急性早幼粒细胞白血病
不利影响
三氧化二砷
内科学
中期分析
随机对照试验
随机化
外科
儿科
维甲酸
基因
生物化学
化学
细胞凋亡
作者
Minghua Yang,Wuqing Wan,Jie‐Si Luo,Mincui Zheng,Ke Huang,Lihua Yang,Huirong Mai,Jian Li,H Q Chen,Xiaofei Sun,Riyang Liu,Guo‐Hua Chen,Xiaoqin Feng,Zhiyong Ke,Бин Ли,Yan‐Lai Tang,Li‐Bin Huang,Xue‐Qun Luo
摘要
, has been shown to be highly effective in treating adult APL. In the treatment of pediatric APL, the safety and efficacy of RIF remains to be confirmed. This randomized, multicenter, and noninferiority trial was conducted to determine whether intravenous ATO can be substituted by oral RIF in the treatment of pediatric APL. From September 2011 to January 2017, among 92 patients who were 16 years old or younger with newly diagnosed PML-RARa positive APL, 82 met eligible criteria and were randomly assigned to ATO (n = 42) or RIF (n = 40) group. The remaining 10 patients did not fulfilled eligible criteria because five did not accept randomization, four died and one had hemiplegia prior to arsenic randomization due to intracranial hemorrhage or cerebral thrombosis. Induction and consolidation treatment contained ATO or RIF, all-trans-retinoic acid and low intensity chemotherapy. End points included event-free survival (EFS), adverse events and hospital days. After a median 3-year follow-up, the estimated 5-year EFS was 100% in both groups, and adverse events were mild. However, patients in the RIF group had significantly less hospital stay than those in the ATO group. This interim analysis shows that oral RIF is as effective and safe as intravenous ATO for the treatment of pediatric APL, with the advantage of reducing hospital stay. Final trial analysis will reveal mature outcome data.
科研通智能强力驱动
Strongly Powered by AbleSci AI